Printer Friendly

IGEN MUST PRODUCE DOCUMENTS ON EISAI RELATIONSHIP.

The U.S. District Court for the District of Maryland has granted a motion by Roche Diagnostics GmbH to compel IGEN to produce documents pertaining to IGEN's relationship with Eisai Ltd ("Eisai"). Eisai is a Japanese diagnostic company which had licensed IGEN's electrochemiluminescence ("ECL") technology in 1990.

Roche Diagnostics and IGEN are currently in litigation over claims surrounding the License and Technology Development Agreement between Roche Diagnostics and IGEN entered in 1992 relating to that same ECL technology. Roche Diagnostics has a number of claims against IGEN, including a claim that IGEN induced Roche Diagnostics into entering the License and Technology Development Agreement in 1992 by misstating the scope of Eisai's ECL rights in Japan, and IGEN's intentions with respect to the expansion of Eisai's ECL rights in the future. Roche Diagnostics also states that IGEN has breached this Agreement by granting additional rights to Eisai in Japan, which infringe upon the worldwide, exclusive rights granted to Roche Diagnostics by IGEN under the Agreement.

IGEN had declined to produce documents relating to Eisai, thus requiring Roche Diagnostics to seek an order from the Court. The Court has now ordered IGEN to produce promptly those documents for Roche Diagnostics. The litigation between Roche Diagnostics and IGEN was initiated in September 1997 stemming from a dispute between the parties relative to the Agreement.

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative products and services address needs for the prevention, diagnosis and treatment of disease, thus enhancing people's well-being and quality of life. Roche has approximately 63,900 employees and sells its products in over 170 countries. The Roche Group posted sales of 20.3 billion Swiss francs in the first nine months of 2000. In the first half of 2000 the company's net income amounted to 3 billion Swiss francs. It invested 1.9 billion Swiss francs in research and development. Through the company's Diagnostics Division, innovative testing products and services are made available to physicians, patients, hospitals and laboratories worldwide.

For more information, call 312-240-3389.
COPYRIGHT 2001 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Feb 1, 2001
Words:350
Previous Article:BIOMARIN'S RHASB GETS EUROPEAN ORPHAN DRUG DESIGNATION.
Next Article:INTERMUNE FILES NDS FOR ACTIMMUNE IN CANADA.
Topics:


Related Articles
BRIEFCASE HOMEBUILDER.COM JOINS WITH YAHOO.
IGEN supplies botulinum toxin tests to USDA's Food Safety and Inspection Service.
Research giant to build 200,000 s/f HQ facility.
Eisai Establishes Sales Subsidiary in Sweden.
Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters